HighCape Capital ($CAPA) agreed to a $7.6 million settlement to resolve claims it misled investors about Quantum-Si’s readiness for commercial launch and business outlook in connection with their SPAC merger.
In June 2021, HighCape Capital, a SPAC, merged with Quantum-Si, a biotech firm focused on single-molecule protein sequencing. However, it was later accused of providing misleading information about Quantum-Si’s product development, commercialization prospects, and financial projections leading up to and after the merger. Following this, the stock dropped by 70%, and investors filed a lawsuit.
On June 10, 2021: HighCape completed its merger with Quantum-Si, and the combined company began trading as $QSI.
Between 2022 and 2023: Quantum-Si missed growth and commercialization targets, and $QSI shares declined over 70%, leading to significant investor losses.
In May 2024: Shareholders filed a class action citing material omissions and misstatements.
In January, 2026: The court set May 6, 2026, as the deadline to submit claims for the settlement.
In June 2021, Quantum-Si Incorporated, a life sciences firm specializing in protein sequencing technology, entered the public markets following a merger with HighCape Capital Acquisition Corp.
At the time of the merger, the company was positioned as a pioneer in commercializing innovative technology for the healthcare sector. The leadership presented optimistic projections regarding commercialization timelines and revenue growth to build momentum.
And, the deal was initially met with significant investor enthusiasm.
However, the post-merger reality shifted as the company struggled to hit its commercialization and revenue milestones.
Quantum-Si faced operational delays and missed key product rollout timelines that had been central to its early projections.
As these challenges became clear to the market, investor confidence evaporated, and $QSI had plummeted over 70% from its post-merger highs.
In response to the decline, investors filed a class action lawsuit, claming that the HighCape Defendants impaired stockholders' redemption rights and provided misleading information in the Proxy statement used to approve the merger.
What Can Investors Expect Now?
HighCape Capital ($CAPA) agreed to a $7.6 million settlement to resolve claims it misled investors about Quantum-Si’s readiness for commercial launch and business outlook in connection with their SPAC merger.
If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section below.